LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

Junshi Biosciences and TopAlliance are set to enter a collaboration with LEO Pharma to distribute and market toripalimab in ...

Toripalimab, independently developed by Junshi Biosciences, is a monoclonal antibody targeting PD-1 for the treatment of ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Rectal Cancer. According to GlobalData, Phase II drugs for Rectal Cancer does not have sufficient ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

The company said it would transfer a low, double-digit percentage of proceeds it receives from toripalimab net sales in ...

From January 7 to 10, 2025, the annual Consumer Electronics Show (CES) took place in Las Vegas, USA, bringing together innovators from 166 countries and regions, including 323 Fortune 500 corporations ...